Ceballos-Baumann A
Neurologisches Krankenhaus München, Zentrum für Parkinson und Bewegungsstörungen.
Ther Umsch. 2007 Jan;64(1):41-53. doi: 10.1024/0040-5930.64.1.41.
Despite great advances in the understanding of the dystonias, treatment for most patients remains symptomatic. Botulinum neurotoxin (BoNT) is the treatment of choice for focal dystonias. Selected issues related to the use of BoNT are highlighted with pertinent illustrations. In certain focal, mainly in generalised dystonias BoNT may not be sufficient or appropriate. Besides BoNT pharmacotherapy, nowadays increasingly deep brain stimulation, psychotherapy, physio- and occupational therapy approaches can be included in the management of dystonic patients. The review focuses on experiences with established management guidelines and new developments in the treatment of dystonias.
尽管在肌张力障碍的认识方面取得了巨大进展,但大多数患者的治疗仍然是对症治疗。肉毒杆菌神经毒素(BoNT)是局灶性肌张力障碍的首选治疗方法。通过相关插图突出显示了与使用BoNT相关的特定问题。在某些局灶性,主要是全身性肌张力障碍中,BoNT可能并不充分或不合适。除了BoNT药物治疗外,如今越来越多的深部脑刺激、心理治疗、物理和职业治疗方法可纳入肌张力障碍患者的管理中。本综述重点关注既定管理指南的经验以及肌张力障碍治疗的新进展。